(Celecoxib + valacyclovir hydrochloride) is under clinical development by Dogwood Therapeutics and currently in Phase II for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID). According to GlobalData, Phase II drugs for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Celecoxib + valacyclovir hydrochloride) LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Celecoxib + valacyclovir hydrochloride) overview
IMC-2 a combination of valacyclovir hydrochloride and celecoxib is under development for the treatment of long COVID, otherwise known as post-acute sequelae of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome virus 2 (SARS-CoV-2) and symptoms such as fatigue, sleep, attention, pain, autonomic function and anxiety. It acts by targeting DNA polymerase and cyclooxegenase-2 (COX-2) and cyclooxegenase-1 (COX-1) enzymes.
Dogwood Therapeutics overview
Dogwood Therapeutics, formerly Virios Therapeutics Inc, is a biotech company that develops novel treatments for the treatment of fibromyalgia and other related syndromes. The company’s pipeline products include NRP-1, a throat spray that is used to treat viral pharyngitis that provides relief to cancer patients undergoing head and neck radiation; IMC-1, a novel proprietary fixed dose combination medication that is designed to treat chronic tissue-resident herpes simplex virus type 1. It also conducts research on various chronic ailments. The company collaborates with other organizations for their pipeline development, licensing and commercialization. Dogwood Therapeutics is headquartered in Tuscaloosa, Alabama, the US.
For a complete picture of (Celecoxib + valacyclovir hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.